Screening for dyslipidemia in younger adults: A systematic review for the U.S. Preventive services task force

Roger Chou, Tracy Dana, Ian Blazina, Monica Daeges, Christina Bougatsos, Thomas L. Jeanne

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Background: Dyslipidemia may occur in younger adults (defined as persons aged 21 to 39 years) and is an important risk factor for cardiovascular disease. Screening might identify younger adults with asymptomatic dyslipidemia who may benefit from lipid-lowering therapies. Purpose: To update the 2008 U.S. Preventive Services Task Force review on dyslipidemia screening in younger adults. Data Sources: The Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and MEDLINE through May 2016, and reference lists. Study Selection: Randomized, controlled trials; cohort studies; and case-control studies on screening for or treatment of asymptomatic dyslipidemia in adults aged 21 to 39 years. Data Extraction: The plan was for 1 investigator to abstract data and a second to check their accuracy, and for 2 investigators to independently assess study quality; however, no studies met the inclusion criteria. Data Synthesis: No study evaluated the effects of lipid screening versus no screening, treatment versus no treatment, or delayed versus earlier treatment on clinical outcomes in younger adults. In addition, no study evaluated the diagnostic yield of alternative screening strategies (such as targeted screening of persons with a family history of hyperlipidemia vs. general screening) in younger adults. Limitation: No direct relevant evidence. Conclusion: Direct evidence on the benefits and harms of screening for or treatment of dyslipidemia in younger adults remains unavailable. Estimating the potential effects of screening for dyslipidemia in this population requires extrapolation from studies performed in older adults.

Original languageEnglish (US)
Pages (from-to)560-564
Number of pages5
JournalAnnals of Internal Medicine
Volume165
Issue number8
DOIs
StatePublished - Oct 18 2016

Fingerprint

Advisory Committees
Dyslipidemias
Young Adult
Therapeutics
Research Personnel
Lipids
Information Storage and Retrieval
Hyperlipidemias
MEDLINE
Case-Control Studies
Cohort Studies
Cardiovascular Diseases
Randomized Controlled Trials
Databases
Population

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Screening for dyslipidemia in younger adults : A systematic review for the U.S. Preventive services task force. / Chou, Roger; Dana, Tracy; Blazina, Ian; Daeges, Monica; Bougatsos, Christina; Jeanne, Thomas L.

In: Annals of Internal Medicine, Vol. 165, No. 8, 18.10.2016, p. 560-564.

Research output: Contribution to journalReview article

Chou, Roger ; Dana, Tracy ; Blazina, Ian ; Daeges, Monica ; Bougatsos, Christina ; Jeanne, Thomas L. / Screening for dyslipidemia in younger adults : A systematic review for the U.S. Preventive services task force. In: Annals of Internal Medicine. 2016 ; Vol. 165, No. 8. pp. 560-564.
@article{a26edd4b468c4beebdf1b75011e04dfe,
title = "Screening for dyslipidemia in younger adults: A systematic review for the U.S. Preventive services task force",
abstract = "Background: Dyslipidemia may occur in younger adults (defined as persons aged 21 to 39 years) and is an important risk factor for cardiovascular disease. Screening might identify younger adults with asymptomatic dyslipidemia who may benefit from lipid-lowering therapies. Purpose: To update the 2008 U.S. Preventive Services Task Force review on dyslipidemia screening in younger adults. Data Sources: The Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and MEDLINE through May 2016, and reference lists. Study Selection: Randomized, controlled trials; cohort studies; and case-control studies on screening for or treatment of asymptomatic dyslipidemia in adults aged 21 to 39 years. Data Extraction: The plan was for 1 investigator to abstract data and a second to check their accuracy, and for 2 investigators to independently assess study quality; however, no studies met the inclusion criteria. Data Synthesis: No study evaluated the effects of lipid screening versus no screening, treatment versus no treatment, or delayed versus earlier treatment on clinical outcomes in younger adults. In addition, no study evaluated the diagnostic yield of alternative screening strategies (such as targeted screening of persons with a family history of hyperlipidemia vs. general screening) in younger adults. Limitation: No direct relevant evidence. Conclusion: Direct evidence on the benefits and harms of screening for or treatment of dyslipidemia in younger adults remains unavailable. Estimating the potential effects of screening for dyslipidemia in this population requires extrapolation from studies performed in older adults.",
author = "Roger Chou and Tracy Dana and Ian Blazina and Monica Daeges and Christina Bougatsos and Jeanne, {Thomas L.}",
year = "2016",
month = "10",
day = "18",
doi = "10.7326/M16-0946",
language = "English (US)",
volume = "165",
pages = "560--564",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "8",

}

TY - JOUR

T1 - Screening for dyslipidemia in younger adults

T2 - A systematic review for the U.S. Preventive services task force

AU - Chou, Roger

AU - Dana, Tracy

AU - Blazina, Ian

AU - Daeges, Monica

AU - Bougatsos, Christina

AU - Jeanne, Thomas L.

PY - 2016/10/18

Y1 - 2016/10/18

N2 - Background: Dyslipidemia may occur in younger adults (defined as persons aged 21 to 39 years) and is an important risk factor for cardiovascular disease. Screening might identify younger adults with asymptomatic dyslipidemia who may benefit from lipid-lowering therapies. Purpose: To update the 2008 U.S. Preventive Services Task Force review on dyslipidemia screening in younger adults. Data Sources: The Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and MEDLINE through May 2016, and reference lists. Study Selection: Randomized, controlled trials; cohort studies; and case-control studies on screening for or treatment of asymptomatic dyslipidemia in adults aged 21 to 39 years. Data Extraction: The plan was for 1 investigator to abstract data and a second to check their accuracy, and for 2 investigators to independently assess study quality; however, no studies met the inclusion criteria. Data Synthesis: No study evaluated the effects of lipid screening versus no screening, treatment versus no treatment, or delayed versus earlier treatment on clinical outcomes in younger adults. In addition, no study evaluated the diagnostic yield of alternative screening strategies (such as targeted screening of persons with a family history of hyperlipidemia vs. general screening) in younger adults. Limitation: No direct relevant evidence. Conclusion: Direct evidence on the benefits and harms of screening for or treatment of dyslipidemia in younger adults remains unavailable. Estimating the potential effects of screening for dyslipidemia in this population requires extrapolation from studies performed in older adults.

AB - Background: Dyslipidemia may occur in younger adults (defined as persons aged 21 to 39 years) and is an important risk factor for cardiovascular disease. Screening might identify younger adults with asymptomatic dyslipidemia who may benefit from lipid-lowering therapies. Purpose: To update the 2008 U.S. Preventive Services Task Force review on dyslipidemia screening in younger adults. Data Sources: The Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and MEDLINE through May 2016, and reference lists. Study Selection: Randomized, controlled trials; cohort studies; and case-control studies on screening for or treatment of asymptomatic dyslipidemia in adults aged 21 to 39 years. Data Extraction: The plan was for 1 investigator to abstract data and a second to check their accuracy, and for 2 investigators to independently assess study quality; however, no studies met the inclusion criteria. Data Synthesis: No study evaluated the effects of lipid screening versus no screening, treatment versus no treatment, or delayed versus earlier treatment on clinical outcomes in younger adults. In addition, no study evaluated the diagnostic yield of alternative screening strategies (such as targeted screening of persons with a family history of hyperlipidemia vs. general screening) in younger adults. Limitation: No direct relevant evidence. Conclusion: Direct evidence on the benefits and harms of screening for or treatment of dyslipidemia in younger adults remains unavailable. Estimating the potential effects of screening for dyslipidemia in this population requires extrapolation from studies performed in older adults.

UR - http://www.scopus.com/inward/record.url?scp=84992630856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992630856&partnerID=8YFLogxK

U2 - 10.7326/M16-0946

DO - 10.7326/M16-0946

M3 - Review article

C2 - 27538032

AN - SCOPUS:84992630856

VL - 165

SP - 560

EP - 564

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 8

ER -